Evaluation of the Radiocobalt-Labeled [MMA-DOTA-Cys(61)]-Z(HER2:2395)-Cys Affibody Molecule for Targeting of HER2-Expressing Tumors
2010 (English)In: Molecular Imaging and Biology, ISSN 1536-1632, E-ISSN 1860-2002, Vol. 12, no 1, 54-62 p.Article in journal (Refereed) Published
Imaging using positron emission tomography (PET) in the field of nuclear medicine is becoming increasingly important. The aim of this study was to develop a method for labeling of affibody molecules with radiocobalt for PET applications. The human epidermal growth factor receptors type 2 (HER2) binding affibody molecule DOTA-Z(2395)-C was radiolabeled with (57)Co (used as a surrogate of (55)Co). The binding specificity and cellular processing of the labeled compound was studied in vitro followed by in vivo characterization in normal and tumor-bearing mice. Furthermore, a comparative biodistribution study was performed with a (111)In-labeled counterpart. DOTA-Z(2395)-C was successfully labeled with radiocobalt with nearly quantitative yield. The compound displayed good retention on cells over time and high tumor accumulation of radioactivity in animal studies. Imaging studies showed clear visualization of HER2-positive tumors. Furthermore, the radiocobalt label provided better tumor-to-organ ratios than (111)In. Radiocobalt is a promising label for affibody molecules for future PET applications.
Place, publisher, year, edition, pages
2010. Vol. 12, no 1, 54-62 p.
PET, Cobalt, Affibody molecule, HER2, Imaging
Medical and Health Sciences Natural Sciences
IdentifiersURN: urn:nbn:se:kth:diva-40872DOI: 10.1007/s11307-009-0238-8ISI: 000273479300008PubMedID: 19557480OAI: oai:DiVA.org:kth-40872DiVA: diva2:442588
QC 201109222011-09-222011-09-222011-09-22Bibliographically approved